Achiko AG (XSWX:ACHI) Common Stock : CHF1.35 Mil (As of Jun. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Achiko AG Common Stock?

Achiko AG's quarterly common stock increased from Jun. 2021 (CHF1.12 Mil) to Dec. 2021 (CHF1.28 Mil) and increased from Dec. 2021 (CHF1.28 Mil) to Jun. 2022 (CHF1.35 Mil).

Achiko AG's annual common stock increased from Dec. 2019 (CHF0.09 Mil) to Dec. 2020 (CHF1.00 Mil) and increased from Dec. 2020 (CHF1.00 Mil) to Dec. 2021 (CHF1.28 Mil).

Achiko AG Common Stock Historical Data

The historical data trend for Achiko AG's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achiko AG Common Stock Chart

Achiko AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Common Stock

0.08

0.09

1.00

1.28

Achiko AG Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Common Stock	Get a 7-Day Free Trial			0.90	1.00	1.12	1.28	1.35

Achiko AG Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Achiko AG (XSWX:ACHI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Achiko AG (XSWX:ACHI) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tessinerplatz 7, Zurich, CHE, CH-8002

Website

https://www.achiko.com

Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Achiko AG (XSWX:ACHI) Headlines

No Headlines